A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumorsIván Díaz-Padilla(University of Toronto), Philippe L. Bédard(Princess Margaret Cancer Centre)Investigational New DrugsJuly 16, 201310.1007/s10637-013-0001-5Cited by 56SaveCiteExport RISWatch citationsRelated PapersMolecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial|Genome Medicine|2016|283First‐in‐human trial of the PI3Kβ‐selective inhibitor SAR260301 in patients with advanced solid tumors|Cancer|2017|34